Rachel McMinn's most recent trade in Neurogene Inc was a trade of 143,500 Employee Stock Option (Right to buy) done . Disclosure was reported to the exchange on March 26, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Neurogene Inc | Rachel McMinn | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2025 | 143,500 | 143,500 | - | - | Employee Stock Option (Right to buy) | |
| Neurogene Inc | Rachel McMinn | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2025 | 23,900 | 1,274,259 | - | 0 | Common Stock | |
| Neurogene Inc | Rachel McMinn | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 20.40 per share. | 22 Nov 2024 | 47,500 | 1,297,859 | - | 20.4 | 969,000 | Common Stock |
| Neurogene Inc | Rachel McMinn | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2024 | 93,282 | 93,282 | - | - | Employee Stock Option (Right to buy) |